Cardioprotezione ed invecchiamento

Size: px
Start display at page:

Download "Cardioprotezione ed invecchiamento"

Transcription

1 55 Congresso SIGG Invecchiamento e longevità: più geni o più ambiente? Firenze, 30/11/ /12/2010 Palazzo dei Congressi SESSIONE DI BIOGERONTOLOGIA Cardioprotezione ed invecchiamento P. Abete, MD, PhD Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche, Cattedra di Geriatria, Università di Napoli Federico II

2

3 Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

4 Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

5 Cardioprotection: definition Myocardial ischemia is the result of an imbalance between myocardial oxygen supply and demand and it was thought to result in irreversible myocyte damage. anti-ischemic It is now demonstrated that in cardiac tissue, submitted to the vaccination!! stress of oxygen and substrate deprivation, endogenous mechanisms of cell survival may be activated. These molecular mechanisms result in physiological conditions of adaptation to ischemia defining the concept of endogenous cardioprotection. Boengler K et al. Cardiovasc Res 2009

6 Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

7 MYOCARDIAL HIBERNATION Rahimtoola SH Circulation 1985 MYOCARDIAL STUNNING Heyndrickx GR et al. J Clin Invest 1975 ISCHEMIC PRECONDITIONING Murry CE et al. Circulation 1986

8 Myocardial stunning Prolonged and fully reversible dysfunction of the ischemic heart which persists after reperfusion despite the normalization of blood flow. Stunning can occur in a number of conditioning following: exercise in the presence of a flow limiting stenosis myocardial infarction where the subendocardium is infarcted and the subepicardium may be stunned for a prolonged period of time; ischemic bout that is induced by angioplasty; ect. Depre C & Vatner SF, Heart Fail Rev 2007

9 Myocardial stunning stunning FLOW-FUNCTION MISMATCH Reperfusion CS=Coronary Stenosis CS 100% Depre C & Vatner SF, Heart Fail Rev 2007

10 Myocardial hibernation Myocardial hibernation represents a condition of chronic ventricular dysfunction in patients with coronary artery disease, which is progressively reversible after revascularization. Myocardial hibernation represent a condition in which: a concomitant reduction in coronary blood flow is present; myocardial necrosis is not present; consequently, myocardial metabolism and function are both reduced. Depre C & Vatner SF, Heart Fail Rev 2007

11 Myocardial hibernation hibernation SMART HEART HYPOTHESIS Flow reduction to 20% Depre C & Vatner SF, Heart Fail Rev 2007

12 Ischemic preconditioning Ischemic preconditioning represents a protection against irreversible damage conferred by brief and repetitive episodes of occlusion/reperfusion preceding a longer episode of potentially lethal Ischemia. The phenomenon is independent of increased collateral blood flow. Ischemic preconditioning occurs in the following conditions: Preinfarction angina Warm-up phenomenon Walk through angina Coronary angioplasty Murry CE et al., Circulation 1986

13 Ischemic preconditioning Infarct size (%) Murry CE et al., Circulation 1986

14 Linking stunning, hibernation, and ischemic preconditioning There is some evidence that myocardial viability cannot be maintained during sustained moderate ischemia for more than a few hours but that chronic hibernation results from repetitive bouts of ischemia-reperfusion; Accordingly, repetitive episodes of ischemic dysfunction followed by stunning create a sustained depression of contractile function; In this context, ischemic preconditioning seems to play a key role in the cardioprotection.

15 Metabolic adaptation during a sequence of no-flow and low-flow ischemia Preconditioning triggers for hibernation? low-flow 2.2 ml/min 10 min. 0 - flow, Ischemic preconditioning! low-flow 2.2 ml/min Ferrari R et al., Circulation 1996

16 SURVIVAL HYPOTHESIS CORONARY STENOSIS Decreased blood flow at rest Decreased metabolism Decreased fuction HIBERNATION Mantained blood flow at rest Repetitive ischemia and reperfusion Chronic STUNNING Chronically depressed Contractile function activation of PRECONDITIONING Depre C & Vatner SF, Heart Fail Rev 2007

17 Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

18 Number of patients in the USA with a heart attack according to age and sex Health Statistics, National Heart, Lung, and Blood Institute, Circulation 2007

19 Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis Odds Ratio (OR) ( ) OR 18.9 % ( ) 8.5 ( ) 0 Age CK >6 x normal Age (years) Age % Mortality OR (95%CI) 80 < Mortality OR 2.2 (95%CI) 3.7 ( ) ( ) % 3.1 ( ) > 6 leads 40 (%) ( ) ( ) ( ) ( ) > ( ) Maggioni AP et al., N Engl J Med 1993

20 Factors leading to shorter survival after acute myocardial infarction in patients aged 65 to 75 years compared with younger patients Mortality (%) years Not adjusted p < Mortality (%) Adjusted for COMORBIDITY p < years 10 0 < 64 years < 64 years Months Months Tofler GH et al, Am J Cardiol 1988

21 Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

22 MYOCARDIAL STUNNING is more evident in senescent than in adult heart Stunning *p<0.01 vs senescent Abete P et al., Exp Gerontol 1999

23 MYOCARDIAL HIBERNATION reduces contractile function more in senescent than in adult heart 100 Hibernation Developed pressure (% of baseline) * * * * Coronary perfusion pressure, mmhg Abete P et al., Exp Gerontol 1999

24 PRECONDITIONING does not prevent postischemic dysfunction in aging heart Ischemic preconditioning B Ischemia Reperfusion B IP Ischemia Reperfusion * * * Adult DP (%) Adult Senescent DP (%) Senescent Time (min) Time (min) P<0.001 vs senescent P. Abete et al., JACC 1996

25 Effect of one 5-min preconditioning cycle (1PC) and three 5-min preconditioning cycles (3PC) on infarct size in young-adult, middle-aged, and aged rat hearts Schulman D et al., J Am Physiol 2001

26 Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart? p < 0.01 p = 0.27 (NS) Angina No Angina 12 Mortality (%) Adults Elderly P. Abete et al., JACC 1997

27 5-years survival curves in adult and elderly patients with and without preinfarction angina 100 Adults 100 Elderly Survival (%) p=0.007 Preinfarction angina (+) Preinfarction angina (-) Survival (%) p=0.47 (NS) Preinfarction angina (+) Preinfarction angina (-) Years Years Ishihara M et al., Am Heart J 2000

28 Myocardial ischemia evaluated by myocardial lactate extraction ratio (MLR) in adult and elderly patients during PTCA MLR (%) 60 p < 0.05 Baseline p < 0.05 Inflation 1 30 Inflation p < 0.01 ADULT ELDERLY Lee T-M et al., Circulation 2002

29 (A) ISCHEMIC PRECONDITIONING PHASE (B) REPERFUSION INJURY SALVAGE KINASE adenosine opioids NE UCN bradykinin ANP-BNP 1 A δ α 1 UR NP A δ α 1 UR GR B 2 adenosine opioids NE UCN bradykinin IGF1-FGF-2 Reduction of NE release in response to preconditioning stimulus (Abete et al., 1996) B 2 GPCR RISK GPCR MPTP PI13K/Akt Reperfusion Injury PI13K enos NO Akt Salvage Kinase sgp GMP pgp GMP P70S6K PKG enos NO ROS p38 ERK 1/2 GSK3β (Mitochondrial Cx43 Permeability Failure of Transition translocation of Pore) PKC isoforms k ATP 4 Key role of MPTP Reduction of phosphorylating mitochondria connexin-43 (Boengler et al. 2007) 2 (Tani et al. 2001) PKC-ε PKC MPTP Enhanced dephosphorylation by protein phosphatases 3 (Fenton et al. 2005) MYOCARDIAL SURVIVAL

30 Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

31 Drugs mimic ischemic preconditioning in different aging experimental model Nicorandil, mithocondrial ATP-K channel opener? Abete P et al., Ageing Res Rev 2009

32 Physical activity and mortality in older men with coronary heart disease Age-adjusted mortality (rate /1000 person years) All cause Non-cardiovascular Cardiovascular 0 I nactive Occasional Light Moderate Moderately vigorous Vigorous Wannamethee SG et al., Lancet 1998

33 Body-mass index (BMI) and rate of death from cardiovascular disease Age-standardized rate ( person/year) > yr yr 75 yr BMI Calle EE et al., N Engl J Med 1999

34 Lifestyle interventions in the elderly Usual aging Successful aging

35 Age-related reduction of ischemic preconditioning by exercise or food-restriction LVDP (% of baseline) Exercised: 30 minutes swimming 5/days/week for 1months. Food-restriction: 60% of ad libitum fed from 12 to 24 months of age * * Ischemia - no IP Ischemia - IP 20 0 *p<0.05 vs no IP Controls Exercised Food-restricted Abete P et al., Ageing Res Rev 2009

36 Age-related reduction of ischemic preconditioning by exercise or food-restriction 30 Physical activity: PASE (Physical Activity Scale for the Eldelry) BMI: Body-mass index no ANGINA ANGINA In-hospital mortality (%) *p<0.05 vs no ANGINA All patients * PASE >90 * BMI Abete P et al., Ageing Res Rev 2009

37 Tandem action of exercise training and food restriction completely preserves ischemic preconditioning in the aging heart B IP Ischemia Riperfusion DP (%) ADULTs SENESCENTs sedentary food-restricted trained trained and food-restricted 20 * * * Time (mins) *p<0.05 vs SENESCENTs food-restricted and trained <0.01 vs ADULTs and SENESCENTs trained and food-restricted Abete P et al, Exp Gerontol, 2005

38 Mortality in elderly patient with AMI stratified for physical activity (PASE) and BMI Mortality (%) p < p < >27.0 p < >90 p < BMI PASE P. Abete et al., Eur J Card Rehab Prev 2009

39 Mortality in elderly patient with acute myocardial infarction stratified for physical activity (PASE) and BMI No Angina 80? 70 Mortality (%) >90 p < (NS) p < (NS) >27.0 p < p < (NS) BMI PASE P. Abete et al., Eur J Card Rehab Prev 2009

40 Mortality in elderly patient with acute myocardial infarction stratified for physical activity (PASE) and BMI Angina 50% Mortality (%) % p < p < > > p < p < BMI PASE P. Abete et al., Eur J Card Rehab Prev 2009

41 Role of preinfarction angina on mortality in elderly patient with acute myocardial infarction stratified for physical activity (PASE) and BMI Odds ratio % 7,0 3,0 2,5 2,0 1,5 1,0 0,5 0,0-0,5 sedentary overweight trained normal weight > PASE > 90 BMI P. Abete et al., Eur J Card Rehab Prev 2009

42 Cardioprotection and aging Cardioprotection: definition Myocardial stunning, hibernation, and ischemic preconditioning Cardioprotection and aging: why? Age-related reduction of cardioprotection Restoration of age-related reduction of cardioprotection Future directions

43 Ischemic PRE-conditioning I R I R ISCHEMIA REPERFUSION PRE Ischemic POST-conditioning ISCHEMIA R I R I REPERFUSION POST

44 Aging mouse hearts are refractory to infarct size reduction with POST-CONDITIONING (post-pc) 100 Control Infarct size (% of LV) * * Post-PC 0 Adult Senescent *p<0.05 vs control Przyklenk K et al., JACC 2008

45 AUTOPHAGY Induced by ischemic preconditioning (IPC) is essential for cardioprotection SHAM Non-IPC Transgenic mice expressing fluorescent fusion of protein mcherry-lc3 allow visualization of autophagosomes IPC Huang C et al., J Cardiovasc Trans Res, 2010

46 Inhibition of AUTOPHAGY reduces cardioprotection autophagy inhibitor=atg5 K130R Huang C et al., J Cardiovasc Trans Res, 2010

47 TAKE HOME MESSAGES Molecular mechanisms of adaptation to ischemia represent the endogenous cardioprotection. Myocardial sunning, hibernation and ischemic preconditioning represent the mechanism against myocardial ischemia in both animal and human studies. Experimental and clinical studies have demonstrated an age-related reduction of cardioprotection mechanisms. Exercise and caloric restriction are able to restore cardioprotection in the aging heart. Post-conditioning and autophagy should be taken into account in the next future.

48

Ischemia and Reperfusion: Pharmacological treatment options

Ischemia and Reperfusion: Pharmacological treatment options Physiologisches Institut Ischemia and Reperfusion: Pharmacological treatment options Prof. Dr. Rainer Schulz Plaque rupture and myocardial ischemia Acute plaque rupture (Stary VI) Ischemic myocardium (ACS,

More information

Reactive oxygen species: Importance for ischemia/reperfusion (injury)

Reactive oxygen species: Importance for ischemia/reperfusion (injury) Physiologisches Institut Reactive oxygen species: Importance for ischemia/reperfusion (injury) Prof. Dr. Rainer Schulz Reactive oxygen species (ROS) in ischemia/reperfusion injury (IRI) ROS GOOD: Endogenous

More information

CLINICAL APPLICATION OF ISCHEMIC PRECONDITIONING IN THE ELDERLY

CLINICAL APPLICATION OF ISCHEMIC PRECONDITIONING IN THE ELDERLY Dose-Response: An International Journal Volume 8 Issue 1 Article 9 3-2010 CLINICAL APPLICATION OF ISCHEMIC PRECONDITIONING IN THE ELDERLY Pasquale Abete Università degli Studi di Napoli Federico II, Naples,

More information

Reperfusion Injury: How Can We Reduce It?

Reperfusion Injury: How Can We Reduce It? MI/CAD: Practical Question in Management of AMI Patients Reperfusion Injury: How Can We Reduce It? Hyun-Jai Cho, M.D., Ph.D Cardiovascular Center & Department of Internal Medicine Seoul National University

More information

cardiac pre and post conditioning

cardiac pre and post conditioning cardiac pre and post conditioning i Stefan De Hert Department of Anesthesiology University Hospital Ghent University of Ghent 2010 Universitair Ziekenhuis Gent Belgium = limited exposition to a small potential

More information

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,

More information

Sean Davidson. The Hatter Cardiovascular Institute University College London, UK

Sean Davidson. The Hatter Cardiovascular Institute University College London, UK Key pathways to ischemia-reperfusion injury Sean Davidson The Hatter Cardiovascular Institute University College London, UK Outline What is ischaemia-reperfusion injury? What causes ischaemia-reperfusion

More information

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,

More information

Reperfusion Effects After Cardiac Ischemia

Reperfusion Effects After Cardiac Ischemia Reperfusion Effects After Cardiac Ischemia Dave Milzman, MD, FACEP Professor and Assistant Dean for Clinical Research Georgetown University School of Medicine Research Director, Depts of Trauma and Emerg

More information

Journal of the American College of Cardiology Vol. 38, No. 4, by the American College of Cardiology ISSN /01/$20.

Journal of the American College of Cardiology Vol. 38, No. 4, by the American College of Cardiology ISSN /01/$20. Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01477-2 Diabetes

More information

Loss of Preconditioning by Attenuated Activation of Myocardial ATP-Sensitive Potassium Channels in Elderly Patients Undergoing Coronary Angioplasty

Loss of Preconditioning by Attenuated Activation of Myocardial ATP-Sensitive Potassium Channels in Elderly Patients Undergoing Coronary Angioplasty Loss of Preconditioning by Attenuated Activation of Myocardial ATP-Sensitive Potassium Channels in Elderly Patients Undergoing Coronary Angioplasty Tsung-Ming Lee, MD; Sheng-Fang Su, PhD; Tsai-Fwu Chou,

More information

Nuovi target e opportunità terapeutiche del danno da riperfusione nello STEMI

Nuovi target e opportunità terapeutiche del danno da riperfusione nello STEMI GUIDATI DA PARADIGMI SEMPRE NUOVI, GLI SCIENZIATI ADOTTANO NUOVI STRUMENTI E PROGETTANO NUOVI STUDI GUARDANDO VERSO NUOVE DIREZIONI Nuovi target e opportunità terapeutiche del danno da riperfusione nello

More information

Journal of the American College of Cardiology Vol. 38, No. 5, by the American College of Cardiology ISSN /01/$20.

Journal of the American College of Cardiology Vol. 38, No. 5, by the American College of Cardiology ISSN /01/$20. Journal of the American College of Cardiology Vol. 38, No. 5, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01560-1 Myocardial

More information

Coronary heart disease (CHD)

Coronary heart disease (CHD) 1 Coronary heart disease (CHD) 2 Institute of Pathological Physiology Martin Vokurka mvoku@lf1.cuni.cz Winter Semester 3 CORONARY CIRCULATION AND MYOCARDIAL METABOLISM 4 Blood flow: resting: 250 ml/min

More information

Ameliorating Reperfusion Injury During Resuscitation from Cardiac Arrest

Ameliorating Reperfusion Injury During Resuscitation from Cardiac Arrest Ameliorating Reperfusion Injury During Resuscitation from Cardiac Arrest Scott T. Youngquist, MD, MSc Associate Professor, Emergency Medicine University of Utah School of Medicine Medical Director, Salt

More information

Basic Mechanisms of Remote Ischemic Conditioning

Basic Mechanisms of Remote Ischemic Conditioning Basic Mechanisms of Remote Ischemic Conditioning Rajesh K Kharbanda Oxford, GB ESC 2012. From Bench to Practice: Bridging the gap Mechanisms and Clinical use of Ischaemic Conditioning Disclosure Shareholder

More information

Master Eudipharm 2012 Introductory Module, Principles of Discovery of Medicine and Development Planning. Nathan Mewton, MD, PhD. September 26 th 2012

Master Eudipharm 2012 Introductory Module, Principles of Discovery of Medicine and Development Planning. Nathan Mewton, MD, PhD. September 26 th 2012 Master Eudipharm 2012 Introductory Module, Principles of Discovery of Medicine and Development Planning * Nathan Mewton, MD, PhD. September 26 th 2012 *A little bit of History *Rabies a viral disease that

More information

Pathophysiology of ischemia-reperfusion injury (and how to protect against it )

Pathophysiology of ischemia-reperfusion injury (and how to protect against it ) Pathophysiology of ischemia-reperfusion injury (and how to protect against it ) Dr Derek J Hausenloy Reader in Cardiovascular Medicine BHF Senior Clinical Research Fellow Honorary Consultant Cardiologist

More information

CONSEQUENCES OF MYOCARDIAL ISCHEMIA

CONSEQUENCES OF MYOCARDIAL ISCHEMIA Página 1 de 8 CONSEQUENCES OF MYOCARDIAL ISCHEMIA Part of "46 - Coronary Blood Flow and Myocardial Ischemia" Metabolic Consequences During ischemia, several metabolic changes occur. Adenosine triphosphate

More information

Ischemic heart disease

Ischemic heart disease Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery

More information

Myocardial ischaemia reperfusion injury: the challenge of translating ischaemic and anaesthetic protection from animal models to humans

Myocardial ischaemia reperfusion injury: the challenge of translating ischaemic and anaesthetic protection from animal models to humans British Journal of Anaesthesia, 117 (S2): ii44 ii62 (2016) doi: 10.1093/bja/aew267 Review Article Myocardial ischaemia reperfusion injury: the challenge of translating ischaemic and anaesthetic protection

More information

Rational use of imaging for viability evaluation

Rational use of imaging for viability evaluation EUROECHO and other imaging modalities 2011 Rational use of imaging for viability evaluation Luc A. Pierard, MD, PhD, FESC, FACC Professor of Medicine Head, Department of Cardiology, CHU Liège, Belgium

More information

Remote Ischemic Preconditioning: Current aspects of mechanisms. Hans Erik Bøtker, Aarhus University Hospital, Skejby, Denmark,

Remote Ischemic Preconditioning: Current aspects of mechanisms. Hans Erik Bøtker, Aarhus University Hospital, Skejby, Denmark, Remote Ischemic Preconditioning: Current aspects of mechanisms Hans Erik Bøtker, Aarhus University Hospital, Skejby, Denmark, Mechanisms Dialysate as a bioassay for riperc Shimizu et al. Clin Sci 2009;117:191-200

More information

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland

More information

presenters 2010 Sameh Sabet Ain Shams University

presenters 2010 Sameh Sabet Ain Shams University Guidelines for PCI in late STEMI presenters 2010 Sameh Sabet Assistant Professor of Cardiology Ain Shams University 29% of MI patients have STEMI. NRMI 4 (Fourth National Registry of Myocardial Infarction),

More information

Gated blood pool ventriculography: Is there still a role in myocardial viability?

Gated blood pool ventriculography: Is there still a role in myocardial viability? Gated blood pool ventriculography: Is there still a role in myocardial viability? Oliver C. Alix, MD Adult Clinical and Nuclear Cardiology St. Luke s Medical Centre - Global City Case Presentation A 62-year-old

More information

Prevention of reperfusion injury in STEMI - Contra

Prevention of reperfusion injury in STEMI - Contra Prevention of reperfusion injury in STEMI - Contra Prof David Erlinge, MD, PhD Lund University, Skane University Hospital, Lund Sweden Disclosure statement: Received speakers fees from the Medicines company,

More information

12 Lead EKG Chapter 4 Worksheet

12 Lead EKG Chapter 4 Worksheet Match the following using the word bank. 1. A form of arteriosclerosis in which the thickening and hardening of the vessels walls are caused by an accumulation of fatty deposits in the innermost lining

More information

OBJECTIVES BACKGROUND METHODS

OBJECTIVES BACKGROUND METHODS Journal of the American College of Cardiology Vol. 36, No. 2, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00722-1 Exercise

More information

Coronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable?

Coronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable? Coronary Revascularization for Severe LV Dysfunction Is s Is the concept of viability testing still viable? Banff 2017 2015 MFMER 3492638-7 Prognosis of Patients With LV Dysfunction and CAD Major determinants

More information

MR Assessment of Myocardial Viability

MR Assessment of Myocardial Viability MR Assessment of Myocardial Viability Definition of Viability Clinical Metabolism: Presence of glucose uptake Perfusion / Perfusion reserve Morphology: Wall thickness, wall thickening Contractility: Recovery

More information

Typical chest pain with normal ECG

Typical chest pain with normal ECG Typical chest pain with normal ECG F. Mut, C. Bentancourt, M. Beretta Nuclear Medicine Service, Asociacion Española Montevideo, Uruguay Clinical history Male 41 y.o. Overweight, hypertension, high cholesterol,

More information

Basic and Clinical Aspects of Ischemic Preconditioning

Basic and Clinical Aspects of Ischemic Preconditioning Home SVCC Area: English - Español - Português Basic and Clinical Aspects of Ischemic Preconditioning Karin Przyklenk, PhD Heart Institute, Good Samaritan Hospital and University of Southern California,

More information

ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG.

ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG. Hyperglycemia and Coronary Events: where is the link? ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG. Cardiovascular (CV) disease is the primary complication of diabetes ~65% of deaths are due to CV disease Coronary

More information

ELECTROPHYSIOLOGICAL CHANGES DURING MYOCARDIAL ISCHAEMIA

ELECTROPHYSIOLOGICAL CHANGES DURING MYOCARDIAL ISCHAEMIA ELECTROPHYSIOLOGICAL CHANGES DURING MYOCARDIAL ISCHAEMIA 1. Definition of myocardial ischaemia "The blood supply to the myocardium is inadequate" (Opie) "The absence of arterial blood flow" (Jennings)

More information

Old and new insights into viability:perfusion and Perfusion Reserve

Old and new insights into viability:perfusion and Perfusion Reserve Old and new insights into viability:perfusion and Perfusion Reserve R.Senior Professor of Clinical Cardiology Consultant Cardiologist and Director of Echo,Royal Brompton Hospital,London and Northwick Park

More information

Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United

Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United States, totaling about 750,000 individuals annually

More information

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

Rationale for Prophylactic Support During Percutaneous Coronary Intervention Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories

More information

There are numerous reviews on the signal transduction of

There are numerous reviews on the signal transduction of Review Molecular Basis of Cardioprotection Signal Transduction in Ischemic Pre-, Post-, and Remote Conditioning Gerd Heusch Abstract: Reperfusion is mandatory to salvage ischemic myocardium from infarction,

More information

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: , 2014

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: , 2014 EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 973-977, 2014 Pharmacological postconditioning with tanshinone IIA attenuates myocardial ischemia reperfusion injury in rats by activating the phosphatidylinositol

More information

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood Revascularization In HFrEF: Are We Close To The Truth Ali Almasood HF epidemic 1-2% of the population have HF At least one-half have heart failure with reduced ejection fraction (HF- REF) The most common

More information

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine

More information

Assessment of Ischemia and Viability

Assessment of Ischemia and Viability EAE Teaching Course Bucharest, 2010 Assessment of Ischemia and Viability Jens-Uwe Voigt Dpt. of Cardiology University Leuven Belgium Assessment of Ischemia & Viability resting wall motion Stress Testing

More information

Ischemia-reperfusion injury (IRI) complicates myocardial

Ischemia-reperfusion injury (IRI) complicates myocardial Arrhythmia/Electrophysiology K ATP Channel Activation Induces Ischemic Preconditioning of the Endothelium in Humans In Vivo M.W. Broadhead, MRCP, FRCA; R.K. Kharbanda, PhD, MRCP; M.J. Peters, PhD, MRCP;

More information

What about aborted infarction?

What about aborted infarction? Unanswered Qs in STEMI management Q3 What about aborted infarction? Is there consensus on the definition? Aborted infarction and TIME to treatment Aborted MI as an outcome measure? Conclusions By Dr Jason

More information

The role of cardiac mitochondria in myocardial ischemia/reperfusion injury. Chad R. Frasier. April, 2012

The role of cardiac mitochondria in myocardial ischemia/reperfusion injury. Chad R. Frasier. April, 2012 The role of cardiac mitochondria in myocardial ischemia/reperfusion injury by Chad R. Frasier April, 2012 Director of Dissertation: David A. Brown Department of Physiology Cardiovascular disease (CVD)

More information

Modificazioni età-correlate del signaling β-adrenergico e basi molecolari dell'utilizzo dei β-bloccanti

Modificazioni età-correlate del signaling β-adrenergico e basi molecolari dell'utilizzo dei β-bloccanti L Italia? Non è un paese per vecchi 53 Congresso Nazionale Società Italiana di Gerontologia e Geriatria Firenze, 26-29 Novembre 2008 Modificazioni età-correlate del signaling β-adrenergico e basi molecolari

More information

Coronary interventions

Coronary interventions Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF

More information

c Ischemia (30 min) Reperfusion (8 w) Supplementary Figure bp 300 bp Ischemia (30 min) Reperfusion (4 h) Dox 20 mg/kg i.p.

c Ischemia (30 min) Reperfusion (8 w) Supplementary Figure bp 300 bp Ischemia (30 min) Reperfusion (4 h) Dox 20 mg/kg i.p. a Marker Ripk3 +/ 5 bp 3 bp b Ischemia (3 min) Reperfusion (4 h) d 2 mg/kg i.p. 1 w 5 w Sacrifice for IF size A subset for echocardiography and morphological analysis c Ischemia (3 min) Reperfusion (8

More information

Myocardial ischemic preconditioning (IP) has been extensively

Myocardial ischemic preconditioning (IP) has been extensively The protective effects of preconditioning decline in aged patients undergoing coronary artery bypass grafting Zhong-Kai Wu, MD a Erkki Pehkonen, MD a Jari Laurikka, MD a Liisa Kaukinen, MD b Eva L. Honkonen,

More information

Adjunctive Therapy to Reduce Infarct Size: Current and Future Challenges

Adjunctive Therapy to Reduce Infarct Size: Current and Future Challenges Adjunctive Therapy to Reduce Infarct Size: Current and Future Challenges Chang-Hwan Yoon, M.D. Cardiovascular Center, Department of Internal Medicine Bundang Hospital 1 1. 빨리뚫어야한다 2013 ACC/AHA STEMI Guideline

More information

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands Cardiogenic Shock Dr. JPS Henriques Academic Medical Center University of Amsterdam The Netherlands Conflict of interest disclosure Research grant Abbott Vascular Research grant Abiomed Inc. Global Impella

More information

Management of Cardiogenic shock. Prof. Christian JM Vrints

Management of Cardiogenic shock. Prof. Christian JM Vrints Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease

More information

Joost Seeger. A thesis submitted in partial fulfilment of the requirements of Liverpool John Moores University for the degree of Doctor of Philosophy.

Joost Seeger. A thesis submitted in partial fulfilment of the requirements of Liverpool John Moores University for the degree of Doctor of Philosophy. Ischaemic preconditioning in exercise and disease: One size fits all? Joost Seeger A thesis submitted in partial fulfilment of the requirements of Liverpool John Moores University for the degree of Doctor

More information

Ischemic Heart Failure

Ischemic Heart Failure 15 th Cardiology Congress of Northern Greece Thessaloniki, May 26-28, 2016 Ischemic Heart Failure Filippos Triposkiadis, MD, FESC, FACC Professor of Cardiology Director, Department of Cardiology Larissa

More information

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in

More information

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial

More information

Myocardial Infarction

Myocardial Infarction Myocardial Infarction MI = heart attack Defined as necrosis of heart muscle resulting from ischemia. A very significant cause of death worldwide. of these deaths, 33% -50% die before they can reach the

More information

Value of cardiac rehabilitation Prof. Dr. L Vanhees

Value of cardiac rehabilitation Prof. Dr. L Vanhees Session: At the interface of hypertension and coronary heart disease haemodynamics, heart and hypertension Value of cardiac rehabilitation Prof. Dr. L Vanhees ESC Stockholm August 2010 Introduction There

More information

Insights into Viability- Function and Contractile Reserve

Insights into Viability- Function and Contractile Reserve Insights into Viability- Function and Contractile Reserve Tom Marwick Cleveland Clinic Conflicts research grants and consulting with GE, Philips, Siemens Off-label use of Definity for assessment of myocardial

More information

Reperfusion Injury, Cardioprotection, and 2 Decades of Failed Studies

Reperfusion Injury, Cardioprotection, and 2 Decades of Failed Studies Reperfusion Injury, Cardioprotection, and 2 Decades of Failed Studies The Dark Side of Reperfusion 2014 MFMER 3327355-7 Reduction of Infarct Size in the Experimental Animal What can be achieved? No reperfusion

More information

Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning

Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning 0031-6997/07/5904-418 458$20.00 PHARMACOLOGICAL REVIEWS Vol. 59, No. 4 Copyright 2007 by The American Society for Pharmacology and Experimental Therapeutics 6002/3284440 Pharmacol Rev 59:418 458, 2007

More information

BEER AND THE HEART: INSIGHTS ON THE EFFECTS ON ALCOHOLIC AND NON-ALCOHOLIC BEER

BEER AND THE HEART: INSIGHTS ON THE EFFECTS ON ALCOHOLIC AND NON-ALCOHOLIC BEER BEER AND THE HEART: INSIGHTS ON THE EFFECTS ON ALCOHOLIC AND NON-ALCOHOLIC BEER Lina Badimon Cardiovascular Research Center (CRC) CSIC-ICCC Barcelona 7 TH EUROPEAN BEER AND HEALTH SYMPOSIUM BRUSSELS -2014

More information

Cardiogenic Shock. Carlos Cafri,, MD

Cardiogenic Shock. Carlos Cafri,, MD Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and

More information

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection

More information

Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute

Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute 62 year old male Anterior STEMI late presentation, occluded

More information

Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center

Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac

More information

Value of Assessment of Viable and Ischemic Myocardium and Techniques Such as MRI, Radionuclide Imaging

Value of Assessment of Viable and Ischemic Myocardium and Techniques Such as MRI, Radionuclide Imaging Chapter 2 Imaging for Viable and Ischemic Myocardium Value of Assessment of Viable and Ischemic Myocardium and Techniques Such as MRI, Radionuclide Imaging Catalin Loghin and K. Lance Gould Introduction

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial

More information

Χ.Τρίκκα Καρδιολογική Κλινική Νοζοκομείο Ερρίκος Νησνάν

Χ.Τρίκκα Καρδιολογική Κλινική Νοζοκομείο Ερρίκος Νησνάν Χ.Τρίκκα Καρδιολογική Κλινική Νοζοκομείο Ερρίκος Νησνάν Efficacy of Myocardial Contrast Echocardiography in the Diagnosis and Risk Stratification of Acute Coronary Syndrome Am J Cardiol 2005;96:1498 1502

More information

Ischemic Heart Failure

Ischemic Heart Failure Kalymnos Days Hellenic Cardiological Society Kalymnos, June 11, 2016 Ischemic Heart Failure Filippos Triposkiadis, MD, FESC, FACC Professor of Cardiology Director, Department of Cardiology Larissa University

More information

Drug Treatment of Ischemic Heart Disease

Drug Treatment of Ischemic Heart Disease Drug Treatment of Ischemic Heart Disease Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan November, 2014 Categories of Ischemic Heart Disease Fixed "Stable, Effort Angina Variant

More information

SHOCKWAVE THERAPY FOR REFRACTORY ANGINA PECTORIS

SHOCKWAVE THERAPY FOR REFRACTORY ANGINA PECTORIS SHOCKWAVE THERAPY FOR REFRACTORY ANGINA PECTORIS S. Marra MD FESC G. Alunni MD Cardiology 2 Torino University S. Giovanni Battista Hospital Italy Ischemic area by SPECT O.C.83, Female Hypertension Previous

More information

Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained

Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained with MitoTracker (red), then were immunostained with

More information

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post

More information

Borja Ibanez, MD PhD FESC. - Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC). - Fundación Jiménez Díaz Hospital.

Borja Ibanez, MD PhD FESC. - Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC). - Fundación Jiménez Díaz Hospital. STEMI 1: Timing, Mechanical Type and Pharmacology of Reperfusion: The Three Main Challenges to Decrease Infarct Size and Increase Viability Borja Ibanez, MD PhD FESC. - Centro Nacional de Investigaciones

More information

Revascularization of ischemic LV dysfunction: past, present and future

Revascularization of ischemic LV dysfunction: past, present and future Revascularization of ischemic LV dysfunction: past, present and future Paolo G Camici, MD, FESC, FACC, FAHA, FRCP Vita-Salute University and San Raffaele Scientific Institute Milan Advances in Cardiovascular

More information

Integrative cardiovascular physiology: a primer to hypothesis driven research

Integrative cardiovascular physiology: a primer to hypothesis driven research Integrative cardiovascular physiology: a primer to hypothesis driven research Peter B. Raven, Ph.D. Univ. of N. TX. HSC @ Fort Worth & Craig G. Crandall, Ph.D. Inst. of Ex. and Environ. Med. @ Dallas Founded

More information

University of Milan spin-off founded in 2004 and now fully owned by Genextra S.p.A.

University of Milan spin-off founded in 2004 and now fully owned by Genextra S.p.A. Mitochondrial Platform Targeting the Permebility Transition Pore Company Overview University of Milan spin-off founded in 2004 and now fully owned by Genextra SpA Focused on identifying and advancing novel

More information

Coronary Revascularization in Patients witj Severe LV Dysfunction.: Is the concept of viability still viable?

Coronary Revascularization in Patients witj Severe LV Dysfunction.: Is the concept of viability still viable? Coronary Revascularization in Patients witj Severe LV Dysfunction.: Implications of the STICH trial Is the concept of viability still viable? Banff 2016 3041435-1 Prognosis of Patients With LV Dysfunction

More information

Screening for Asymptomatic Coronary Artery Disease: When, How, and Why?

Screening for Asymptomatic Coronary Artery Disease: When, How, and Why? Screening for Asymptomatic Coronary Artery Disease: When, How, and Why? Joseph S. Terlato, MD FACC Clinical Assistant Professor, Brown Medical School Coastal Medical Definition The presence of objective

More information

CORONARY ARTERY DISEASES

CORONARY ARTERY DISEASES CORONARY ARTERY DISEASES It has been estimated that over one third of the population eventually will die of CAD, and 20% will develop symptoms when younger than age 60 years. ANATOMY OF THE CORONARY ARTERIES

More information

The life after myocardial infarction: a long quiet river?

The life after myocardial infarction: a long quiet river? The life after myocardial infarction: a long quiet river? Cardiac rehabilitation: for whom and how? Dr. Barnabas GELLEN MD, PhD, FESC Poitiers JESFC 2018 - Paris Conflicts of interest Speaker honoraria

More information

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern

More information

Mechanisms and role of contrast echocardiography

Mechanisms and role of contrast echocardiography Mechanisms and role of contrast echocardiography Seol Sang-Hoon Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea Physical Principles of Contrast Ultrasound Contrast echocardiography

More information

OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION

OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION FEROZ MEMON*, LIAQUAT CHEEMA**, NAND LAL RATHI***, RAJ KUMAR***, NAZIR AHMED MEMON**** OBJECTIVE: To compare morbidity,

More information

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect

More information

Management of the coronary patient in Roberto Ferrari

Management of the coronary patient in Roberto Ferrari Management of the coronary patient in 2011 Roberto Ferrari What is new in treatment of stable CAD? In the era of interventional cardiology, is chronic stable angina a rare disease? Stable angina pectoris

More information

Angiotensin-converting enzyme inhibitors potentiate subthreshold preconditioning through NO and mitok ATP. channel

Angiotensin-converting enzyme inhibitors potentiate subthreshold preconditioning through NO and mitok ATP. channel Acta Physiologica Sinica, August 25, 2005, 57 (4): 453-460 http://www.actaps.com.cn 453 ATP 1 1 1 2 2 2,* 1 313000 2 310006 Langendorff ( ) ( ) (angiotensin-converting enzyme inhibitors, ACEI) (nitric

More information

Improving STEMI outcomes in Denmark. Michael Rahbek Schmidt, MD, PhD. Aarhus University Hospital Skejby Denmark

Improving STEMI outcomes in Denmark. Michael Rahbek Schmidt, MD, PhD. Aarhus University Hospital Skejby Denmark Improving STEMI outcomes in Denmark Michael Rahbek Schmidt, MD, PhD. Aarhus University Hospital Skejby Denmark Presenter Disclosure Information Study funded by Fondation Leducq Michael Rahbek Schmidt The

More information

Management of stable CAD FFR guided therapy: the new gold standard

Management of stable CAD FFR guided therapy: the new gold standard Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC Should patients

More information

Recovering Hearts. Saving Lives.

Recovering Hearts. Saving Lives. Recovering Hearts. Saving Lives ṬM The Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial November 218 Recovering Hearts. Saving Lives. LEGAL DISCLAIMERS This presentation includes select slides

More information

CPR flow to prime the ischemic heart during cardiac arrest?

CPR flow to prime the ischemic heart during cardiac arrest? CPR flow to prime the ischemic heart during cardiac arrest? BY MARK G ANGELOS, MAHMOOD KHAN Abstract Cardiac arrest is unique among cardiac ischemic syndromes in that all circulation must be generated

More information

6. Lochner, A., Tromp, E., Mouton, R. Signal transduction in myocardial ischaemia and reperfusion. Mol Cell Biochem., 160/161: , 1996.

6. Lochner, A., Tromp, E., Mouton, R. Signal transduction in myocardial ischaemia and reperfusion. Mol Cell Biochem., 160/161: , 1996. PUBLICATIONS IN PEER-REVIEWED JOURNALS: 1. Moolman, J.A., Genade, S., Tromp, E., Lochner, A. Ischaemic preconditioning: interaction with antiadrenergic interventions. J Mol Cell Cardiol 27(6): A161, June

More information

Forum Minireview. Tetsuji Miura 1, *, Masahiro Nishihara 1, and Takayuki Miki 1

Forum Minireview. Tetsuji Miura 1, *, Masahiro Nishihara 1, and Takayuki Miki 1 J Pharmacol Sci 109, 162 167 (2009)2 Journal of Pharmacological Sciences 2009 The Japanese Pharmacological Society Forum Minireview Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-

More information

1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI).

1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI). 1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI). 5- cardiogenic shock (massive MIs >40% of the left ventricle)

More information

Fetal gene upregulation by 1-wk TAC is significantly increased in mice lacking RGS2.

Fetal gene upregulation by 1-wk TAC is significantly increased in mice lacking RGS2. 3562-RG-1 Supplementary Figure 1 Fetal gene upregulation by 1-wk is significantly increased in mice lacking RGS2. ANP(Nppa) /BNP(Nppb) A-type and B-type natriuretic peptide; β-mhc (Myh7) beta myosin heavy

More information

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical

More information

Novel Strategies in Cardioprotection against Ischemia/Reperfusion Injury

Novel Strategies in Cardioprotection against Ischemia/Reperfusion Injury Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2005 Novel Strategies in Cardioprotection against Ischemia/Reperfusion Injury Fadi N. Salloum Virginia Commonwealth

More information